Anti-Mouse CD22 – Purified in vivo PLATINUM™ Functional Grade

Clone Cy34.1 is a monoclonal antibody targeting mouse CD22 that is widely used in in vivo mouse studies, primarily for applications involving B cell depletion, modulation of B cell function, and flow cytometry analysis of B cell populations.

Key research uses of clone Cy34.1 in mice:

• B Cell Depletion: Cy34.1 is frequently used in combination with other antibodies (notably anti-CD19 clone 1D3 and anti-rat ? Light Chain clone MAR 18.5) to achieve efficient in vivo depletion of B cells for cell-specific functional studies. This is valuable for exploring B cell roles in immunology, autoimmunity, and infectious disease models.

• Modulation of B Cell Proliferation: The antibody has been shown to augment B cell proliferation in response to stimuli like LPS (lipopolysaccharide) or anti-IgM, making it useful in experiments investigating B cell activation pathways and mechanisms of tolerance or autoimmunity.

• Flow Cytometry and Immunophenotyping: Cy34.1 is used as a marker for murine CD22 expression to identify and analyze mature B cell subsets, including follicular, marginal zone, B-1, and plasma cells by flow cytometry. Typical staining concentrations recommended are ? 1.0??g per 10^6 cells in a volume of 100??l for cytometry applications.

• Immunoprecipitation: The antibody is suitable for immunoprecipitation of CD22-positive cells or proteins in murine samples.

Technical features for in vivo use:

• Low endotoxin formulations (<2 EU/mg, often <1 EU/mg) are standard to prevent immune activation unrelated to target engagement during in vivo experiments.
• High purity antibody preparations (>95% or >98%) suitable for animal work ensure reproducibility and minimal off-target effects.
• The antibody is unconjugated in most cases, but can be supplied in conjugated forms if needed for specialized assays.

Summary Table: Common In Vivo Research Uses of Clone Cy34.1

CD22 is a B cell-specific marker involved in B cell adhesion and inhibition of B cell activation; thus, in vivo use of Cy34.1 enables the dissection of B cell biology, tolerance, and disease mechanisms.

Cy34.1 is suitable for both acute depletion and chronic modulation studies, depending on dosing and experimental design. Always consult supplier datasheets and published protocols for optimal dosing, formulation, and administration routes specific to each study.

Commonly used antibodies or proteins in combination with Cy34.1 (anti-mouse CD22) in the literature include antibodies targeting other B cell markers, Fc gamma receptors, and immunoglobulin chains, as well as isotype controls for experimental rigor.

Key examples include:

• Anti-mouse Ig µ chain: Often used alongside Cy34.1 to stimulate or analyze B cell proliferation, particularly in response to lipopolysaccharide (LPS) or other signals.
• Anti-CD19 (clone 1D3): Utilized for in vivo B cell depletion experiments in conjunction with Cy34.1, as CD19 is another pan-B cell marker.
• Anti-rat ? Light Chain (clone MAR 18.5): Employed in immunoprecipitation and depletion protocols where Cy34.1 is used to target CD22.
• Fc?RIIb (CD32b) antibodies: Sometimes studied together with Cy34.1 to examine regulatory mechanisms and co-expression on B cells.
• Isotype controls: Typically, a mouse IgG1 isotype control is recommended when using Cy34.1 to ensure specificity of binding in flow cytometry and other assays.

In flow cytometry and immunoprecipitation protocols, Cy34.1 is often part of panels to identify and characterize B cells, sometimes with additional markers such as CD19, CD21, CD23, or pan-B cell surface proteins.

Some studies also recommend confirming surface marker expression using two independent antibody clones (for example, different anti-CD22 clones such as 2D6/NIM-R6) to avoid artifacts caused by antibody interactions or changes in Fc receptor expression.

Overall, Cy34.1 is typically used in multi-antibody panels for flow cytometry, B cell subset analysis, depletion experiments, and functional studies, and is frequently paired with antibodies against other B cell-associated proteins or relevant isotype controls.

Clone Cy34.1 is a monoclonal antibody targeting mouse CD22, and its citations in scientific literature primarily report key findings in immunology and neurobiology:

• CD22 Modulation in Neuroinflammation: Anti-murine CD22 antibody (Clone Cy34.1) infusion in mice improves cognitive function and alleviates amyloid ?-induced neuroinflammation, especially in aging models. This demonstrates a potential therapeutic role in neurodegenerative disease contexts.

• B Cell Regulation and Autoimmunity: Cy34.1 recognizes CD22, which is expressed mainly on mature B cells, B-1 cells, and plasma cells. CD22 is involved in B cell adhesion and acts as a negative regulator of B cell activation, thus playing a protective role against autoimmunity. Cy34.1 has augmented B cell proliferation when stimulated with LPS or anti-mouse Ig µ chain.

• Flow Cytometry and B Cell Marker Analysis: Cy34.1 is widely used in flow cytometry to identify and characterize B cell subsets in murine models, though one study highlights that its binding to CD22 may depend on Fc?RIIb stabilization. This means researchers should verify CD22 expression using multiple methods for accurate phenotyping due to antibody-binding dependencies.

• Recommended Applications and Utility: Cy34.1 is validated for:

  • In vivo B cell depletion (often in combination with other antibodies)
  • Flow cytometry
  • Immunoprecipitation

• Technical Specifications:

  • Mouse IgG1, ? isotype
  • Unconjugated product, conjugation available
  • High purity (>95%)
  • No stabilizers or preservatives

Additional notes:

• Clone Cy34.1’s activity and binding characteristics may be influenced by Fc receptor expression, which is crucial for interpreting flow cytometry data and designing therapeutic antibodies.
• CD22 targeting, as shown with Cy34.1, is increasingly studied for its relevance in neurological disorders and B cell-mediated diseases.

These findings establish Cy34.1 as an important reagent for B cell biology research, with implications for therapeutic approaches in immune and neurodegenerative disease models.

Dosing regimens for clone Cy34.1 (anti-mouse CD22 monoclonal antibody) can vary across mouse models depending on experimental objectives, targeted cell populations, administration routes, and combination therapies. Published protocols and supplier guidelines provide limited, model-dependent specifics.

Key insights:

• Common use: Cy34.1 is primarily utilized for in vivo B cell depletion, often in combination with other antibodies such as anti-CD19 (clone 1D3) and anti-rat ? Light Chain (clone MAR 18.5).
• Reported applications: In studies, Cy34.1 has been administered via intravenous infusion or direct brain infusion in mouse models, depending on tissue targeting—peripheral or CNS.

Specific Regimen Examples

• Peripheral B cell depletion (e.g., immune suppression, autoimmune models):
  • Combination therapy is typical, but details on specific dosing (mg/kg, frequency) are rarely stated explicitly in product literature or generic protocol listings. Researchers typically optimize dosing based on experimental endpoints such as depletion efficiency and absence of toxicity.
• Neuroinflammation model (aging, Alzheimer’s disease):
  • Brain infusion application: Cy34.1 was delivered directly to the brain of aged mice in published research. While the exact dose is not listed in the text of the cited result, this route implies lower systemic doses and region-specific targeting.
  • Study reports significant functional effects (cognitive improvement) without specifying the dosing schedule in summary or figures. Protocol details would be located in supplementary materials or complete methods sections.

Factors Affecting Dosing Variation

• Route of administration: Intravenous vs. local (e.g., intracerebral) affects systemic exposure and required dose.
• Mouse strain and age: Different mouse strains or aged models may exhibit variable sensitivity or antibody pharmacokinetics, leading to adjustment in dose or frequency.
• Combination with other agents: When used with anti-CD19 or anti-rat ? Light Chain antibodies, titration and scheduling are adjusted to maximize depletion and minimize immune reactions.
• Experimental application: Neuroinflammation models, autoimmune models, and depletion studies may target distinct B cell populations and thus require different antibody amounts.

Consensus

• No standardized dosing: There is no universally fixed dosing schedule for Cy34.1 antibody; protocols are tailored to model, administration route, and purpose.
• Supplier recommendations: Product datasheets do not specify dosing, instead highlighting applications and combination uses, suggesting researchers must optimize concentrations empirically for their mouse strain and study design.
• Published literature: Method sections in individual studies are the most authoritative source for regimen specifics for particular models, but these details are not always present in summary publications.

In summary, dosing regimens for clone Cy34.1 fluctuate across mouse models depending on route, combination therapies, and study objectives, with no standardized protocol. Researchers base dosing decisions on depletion efficacy, cell targeting, toxicity, and experimental requirements.